Back to Search Start Over

Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.

Authors :
Cloyd JM
Sarna A
Arango MJ
Bates SE
Bhutani MS
Bloomston M
Chung V
Dotan E
Ferrone CR
Gambino PF
Goenka AH
Goodman KA
Hall WA
He J
Hogg ME
Jayaraman S
Kambadakone A
Katz MHG
Khorana AA
Ko AH
Koay EJ
Kooby DA
Krishna SG
Larsson LK
Lee RT
Maitra A
Massarweh NN
Mikhail S
Muzaffar M
O'Reilly EM
Palta M
Petzel MQB
Philip PA
Reyngold M
Santa Mina D
Sohal DPS
Sundaresan TK
Tsai S
Turner KL
Vreeland TJ
Walston S
Washington MK
Williams TM
Wo JY
Snyder RA
Source :
JAMA surgery [JAMA Surg] 2024 Dec 04. Date of Electronic Publication: 2024 Dec 04.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Importance: Neoadjuvant therapy (NT) is an increasingly used treatment strategy for patients with localized pancreatic ductal adenocarcinoma (PDAC). Little research has been conducted on cancer care delivery during NT, and the standards for optimal delivery of NT have not been defined.<br />Objective: To develop consensus best practices for delivering NT to patients with localized PDAC.<br />Design, Setting, and Participants: This study used a modified Delphi approach consisting of 2 rounds of voting, and a series of virtual conferences (from October to December 2023) to reach expert consensus on candidate best practice statements generated from a systematic review of the literature and expert opinion. An interdisciplinary panel was formed including 47 North American experts from surgical, medical, and radiation oncology, radiology, pathology, gastroenterology, integrative oncology, anesthesia, pharmacy, nursing, cancer care delivery research, and nutrition as well as patient and caregiver stakeholders.<br />Main Outcome and Measures: Statements that reached 75% agreement or greater were included in final consensus statements.<br />Results: Of the 47 participating panel members, 27 (57.64%) were male, and the mean (SD) age was 47.6 (8.2) years. Physicians reported completing training a mean (SD) 14.6 (8.6) years prior and seeing a mean (SD) 110.6 (38.4) patients with PDAC annually; 35 (77.7%) were in academic practice. Final consensus was reached on 82 best practices for delivering NT. Of these, 38 statements focused on pre-NT practices, including diagnosis and staging (n = 15), evaluation and optimization (n = 20), and decision-making (n = 3); 29 statements defined best practices during NT, including initiation (n = 3), delivery of therapy (n = 8), restaging practices (n = 12), and management of complications during NT (n = 6); and 15 best practices were identified to guide treatment post-NT, focusing on surgery (n = 7), pathology (n = 4), and follow-up (n = 3).<br />Conclusions: Using a modified Delphi consensus technique, best practice guidelines were developed focusing on the optimal standards for delivering NT to patients with localized PDAC. Given the prognostic importance of completing multimodality therapy, efforts to standardize and optimize the delivery of NT represent an immediate opportunity to decrease care variation and improve outcomes for patients with PDAC. Future research should focus on validating and implementing best practice standards into clinical practice.

Details

Language :
English
ISSN :
2168-6262
Database :
MEDLINE
Journal :
JAMA surgery
Publication Type :
Academic Journal
Accession number :
39630427
Full Text :
https://doi.org/10.1001/jamasurg.2024.5191